A Dose Ranging Study of OPT-302 With Ranibizumab in Neovascular (Wet) AMD
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Opthea Limited
- Study ID
- NCT03345082
- Phase
- PHASE2
- Status
- Completed
Conditions
- Neovascular Age-related Macular Degeneration
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- OPT-302 — BIOLOGICALIntravitreal injection
- ranibizumab — BIOLOGICALIntravitreal injection
- sham intravitreal injection — OTHERSham (mock) intravitreal injection
Study Details
A multicentre, randomised, parallel group, sham-controlled, double-masked, dose-ranging study, investigating two doses of OPT-302 in combination with ranibizumab compared with ranibizumab with sham, over six consecutive monthly dosing cycles in participants with neovascular (wet) AMD.
Key Dates
- First listed
- Nov 17, 2017
- Start date
- Nov 6, 2017
- Status verified
- Jan 2020
- Primary completion
- May 14, 2019
- Completion
- May 14, 2019
Study Design
- Enrollment
- 366 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: 0.5 mg ranibizumab with 2.0 mg OPT-3020.5 mg ranibizumab intravitreal injection (0.05 ml) followed by 2.0 mg OPT-302 intravitreal injection (0.05 ml)
- Experimental: 0.5 mg ranibizumab with 0.5 mg OPT-3020.5 mg ranibizumab intravitreal injection (0.05 ml) followed by 0.5 mg OPT-302 intravitreal injection (0.05 ml)
- Sham Comparator: 0.5 mg ranibizumab with sham0.5 mg ranibizumab intravitreal injection (0.05 ml) followed by sham
Primary Outcome Measure
Mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) best corrected visual acuity (BCVA) [ Time Frame: Baseline to Week 24 ]
Locations (55)
Find similar trials in Phoenix, AZ
Related Studies
- Extension Study for the Port Delivery System With Ranibizumab (Portal)PHASE3 · Recruiting · Hoffmann-La Roche · Phoenix, Arizona
- Long-term Follow-Up Study of RGX-314 and Fellow Eye SubstudyPHASE2 · Enrolling By Invitation · AbbVie · Phoenix, Arizona
- A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)PHASE4 · Recruiting · Genentech, Inc. · Mesa, Arizona
- Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)PHASE1/PHASE2 · Recruiting · Skyline Therapeutics (US) Inc. · St. Petersburg, Florida